CDISC Blog
|
![]() |
The Critical Path to TB Drug Regimens (CPTR) is a recently formed collaboration of global pharmaceutical companies; government and regulatory agencies; foundations and donors; academia; and patient advocacy groups. The CPTR initiative was created and is managed by a partnership of the Bill & Melinda Gates Foundation, the Global Alliance for TB Drug Development (Global TB Alliance) and the Critical Path Institute (C-Path).
![]() |
Two new documents relevant to CDISC have now been posted to the FDA website and one announced in the Federal Register. In this blog are a few highlights that I have pulled from each of the documents…but, please read them yourselves and please sign up to attend the webinar on 29 June to hear directly from CBER and CDER representatives, Amy Malla and Dr. Chuck Cooper.
![]() |
Please read the details on the membership page BEFORE you apply. Please also check that your company is not already a member of CDISC here: CDISC Members.To register for a new membership, please supply the following information.